Grifols Full Year 2023 Earnings: EPS Misses Expectations

Grifols (BME:GRF) Full Year 2023 Results

Key Financial Results

• Revenue: €6.59b (up 8.7% from FY 2022).
• Net income: €59.3m (down 72% from FY 2022).
• Profit margin: 0.9% (down from 3.4% in FY 2022). The decrease in margin was driven by higher expenses.
• EPS: €0.087 (down from €0.31 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Grifols EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 59%.

Looking ahead, revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe.

Performance of the market in Spain.

The company's shares are up 5.0% from a week ago.

Risk Analysis

We should say that we've discovered 3 warning signs for Grifols (2 are a bit unpleasant!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.